Antengene’s ATG-101 has received an Orphan Drug designation by the FDA for treatment of patients with pancreatic cancer.

A bispecific antibody, ATG-101 is designed to block the binding of immunosuppressive PD-1/PD-L1 and to stimulate receptors that boost T cell activation.

The treatment aims to deliver enhanced antitumor activity with an improved safety profile, the company said.

ATG-101 could become the first PD-L1/4-1BB bispecific antibody approved for the treatment of pancreatic cancer, Antengene said.